Kyoto iCAP's KYOTO-iCAP 1 Fund has successfully sold its entire stake in Fimecs to Rakuoria Seiyaku, facilitating an acquisition aimed at accelerating pharmaceutical innovations.
Target Company Overview
Fimecs Co., Ltd. was established in January 2018 and is headquartered in Fujisawa, Kanagawa Prefecture. The company specializes in research and development of novel pharmaceuticals that utilize the mechanism of protein degradation. Under the leadership of CEO Yusuke Tominari, Fimecs is focused on advancing innovative therapeutic solutions.
This announcement pertains to the acquisition of Fimecs by Rakuoria Seiyaku Co., Ltd., based in Nagoya, Aichi Prefecture, led by CEO Hirofumi Takeuchi. The entire equity stake held by the KYOTO-iCAP 1 Fund in Fimecs will be sold as part of this transaction.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
Japan's pharmaceutical industry is one of the largest and most advanced in Asia, leveraging the country's strong emphasis on research and development. The industry is supported by a robust regulatory framework, providing a co
Similar Deals
Bain Capital → Mitsubishi Tanabe Pharma
2023
Advantage Partners → Epoch Japan, Inc.
2015
Advantage Partners → Fukuba Dental Co., Ltd.
2015
Advantage Partners → Hokuou Group
2013
ラクオリア創薬株式会社
invested in
ファイメクス株式会社
in 2024
in a Management Buyout / Buy-In (MBO) deal
Disclosed details
Transaction Size: $4M